The paradox of triple negative breast cancer: novel approaches to treatment.
about
The fate of chemoresistance in triple negative breast cancer (TNBC)Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature"An addendum to breast cancer": the triple negative experience.Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsFolate receptor-α (FOLR1) expression and function in triple negative tumorsAndrogen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsClinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancerMiR-34b is associated with clinical outcome in triple-negative breast cancer patientsThe potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy.Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expressionImpact of radiation therapy on survival in patients with triple-negative breast cancer.5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cellsTargeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.First-in-Human Phase 1 Studies in Oncology: The New Challenge for Investigative Sites.T-cadherin is associated with prognosis in triple-negative breast cancerTargeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.The dysregulation of tRNAs and tRNA derivatives in cancer.
P2860
Q26775232-66667760-EEFD-4FBF-990D-C5C65341F9CDQ26779880-C9F5E951-ABAA-4DF5-96A4-7AD6CD4FF5EBQ30277052-B46A77FB-0DF4-468A-84D2-D5ED17869E61Q34646376-B699FB7D-6360-4E1F-9659-BE1C82247ECAQ35225064-85299436-1BF8-429C-B06A-0C04B0858855Q35651216-C317C170-1349-4267-944B-9D75325D3931Q35803370-C5403017-99C4-476B-A822-E26B51A999BCQ35950656-02FAEC1A-FE19-44C2-875F-55094A4CD43EQ37304764-62F2F522-411F-400E-A27F-D578E5C6DC24Q37385219-91E7800A-8220-4A67-8C5D-42E9AD4F54FAQ37395716-4DD94CA5-9C9D-4E24-875A-938F2BE9B558Q37438041-14E93C43-BC90-408B-80D4-F5B9941D7EF3Q37438076-91DA0A9E-3FC0-4436-8959-3BD9A5EEFDAAQ37477489-4BA02AC1-0366-4948-9FB5-537B67F06AD1Q37645090-42D0CF98-8000-4843-B861-8F41D885DEFAQ37697013-77F4FBDA-F953-4A56-8B49-891635D72D2BQ39634771-D0D0A1FC-CB3A-49B6-8DAE-9E138315FEDCQ41612892-F2533565-1C29-4697-ACE7-50E6396C19EBQ47243874-D0FCD09D-2F3B-4BFF-B40F-1A271698BFD7Q53823804-3F5E24E7-ECBB-4F23-B6E7-EB9BF973A319
P2860
The paradox of triple negative breast cancer: novel approaches to treatment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The paradox of triple negative breast cancer: novel approaches to treatment.
@en
The paradox of triple negative breast cancer: novel approaches to treatment.
@nl
type
label
The paradox of triple negative breast cancer: novel approaches to treatment.
@en
The paradox of triple negative breast cancer: novel approaches to treatment.
@nl
prefLabel
The paradox of triple negative breast cancer: novel approaches to treatment.
@en
The paradox of triple negative breast cancer: novel approaches to treatment.
@nl
P2860
P1433
P1476
The paradox of triple negative breast cancer: novel approaches to treatment.
@en
P2093
Monica Fornier
Pierre Fumoleau
P2860
P356
10.1111/J.1524-4741.2011.01175.X
P577
2011-11-20T00:00:00Z